Zinc for colds: what lozenges are really worth

Zinc for colds: what lozenges are really worth
SupplementsImage de l’article

Zinc and colds: the short answer

For prevention, zinc has no demonstrated effect on the risk of catching a cold. As a treatment, it might shorten a cold by around two days, with low certainty. The most favourable signal concerns lozenges left to dissolve, at doses that everyday capsules do not reach and that far exceed the European safety limit.

For most adults, the reasonable option therefore remains not taking it, or trying a lozenge for a few days while accepting real uncertainty. Only one category deserves a firm no: zinc gels and sprays used inside the nose.

The NHS notes that a cold usually improves within one to two weeks. That is the baseline for comparison. A product promising to “beat winter” needs data showing it can beat that timeline.

Prevention: the winter course fails to deliver

Zinc is essential for immune function. True. Concluding that a course of zinc protects against colds is Mitochondria Marketing: using a genuine biological mechanism to sell a product with no demonstrated benefit.

The Cochrane review by Nault and colleagues, published in 2024, brought together 34 randomised trials and 8,526 participants. For prevention, zinc produces little or no reduction in the risk of developing a cold (RR 0.93, 95% CI: 0.85 to 1.01, 9 studies, 1,449 participants, low certainty).

When a cold occurs despite supplementation, its duration probably does not change either (-0.63 days, 95% CI: -1.29 to 0.04, 3 studies, 740 participants, moderate certainty). Symptom severity also appears unchanged.

There is one logical exception: a genuine deficiency should be corrected, but it needs to be documented first. Vidal notes that zinc’s immune-stimulating effect applies to people with a deficiency. The guide to zinc picolinate · FR details requirements and the limitations of blood testing.

Treatment: two fewer days, with a hefty asterisk

In people who already have a cold, Cochrane finds an average reduction in duration of 2.37 days (95% CI: -4.21 to -0.53, 8 studies, 972 participants, low certainty). That figure gets plenty of airtime. Its context, much less.

Heterogeneity reaches an I² of 97%, meaning that the trials strongly disagree. The interval ranges from half a day to more than four days. Crucially, there is no demonstrated improvement in overall symptom severity, with very low certainty.

There is also a price to pay: non-serious adverse effects are probably more frequent (RR 1.34, 95% CI: 1.15 to 1.55, 16 studies, 2,084 participants, moderate certainty). The Cochrane summary in French mainly cites taste disturbances and stomach upset. No treatment trial reported information on serious adverse effects.

The meta-analysis dispute

Hemilä, a researcher at the University of Helsinki who has published on this subject for years, challenges Cochrane’s pooling of the studies. In a co-authored critical analysis in 2024, he and Chalker point out that the main analysis combines lozenges and nasal zinc, with roughly a 4,300-fold dose difference between some trials.

Keeping only adult lozenge trials, they find a 37% reduction in duration (95% CI: 27 to 46%) across five trials. They also stress that there is no evidence of benefit in children. They declare no financial ties, but these figures are reanalyses of their own earlier work.

The dose argument is the most interesting. In 2011, five trials using less than 75 mg per day found no effect. In 2017, seven trials using more than 75 mg per day, with 575 participants, found a 33% reduction in duration (95% CI: 21 to 45%). There is no indication that going beyond 100 mg per day provides any additional benefit.

In 2015, three trials using 80 to 92 mg per day of zinc acetate showed shorter durations of runny nose (34%), congestion (37%) and cough (46%), but no difference in fever or headaches. These trials started within 24 hours of the first symptoms.

The trial that throws cold water on the idea

The most awkward test of the theory comes from the same researcher. In a double-blind randomised trial published in BMJ Open in 2020, Hemilä and colleagues distributed commercial 13 mg zinc acetate lozenges. The instructions: six times a day, totalling 78 mg per day, for a maximum of five days.

Of 253 people randomised, 88 caught a cold and 87 were analysed. The result: no difference in recovery rate over ten days (rate ratio 0.68, 95% CI: 0.42 to 1.08, p = 0.10). During the two days after stopping, participants taking zinc even recovered more slowly. Only 37% of them reported no adverse effects, compared with 69% on placebo.

So one of the researchers most closely associated with zinc published a trial in which a commercial lozenge, at the dose considered effective, did not work. With just 87 people analysed, this remains a small trial, and it does not write off every lozenge. Above all, it shows that the right dose on the label guarantees nothing.

Lozenge, capsule, spray: delivery changes everything

The lozenge: a local-effect hypothesis

The proposed explanation is a local effect: zinc ions released in the throat as the lozenge dissolves. This is a biological hypothesis, not an established fact. Hemilä and Chalker emphasise formulation: certain excipients, such as citric acid, tartaric acid or a mannitol-sorbitol mixture, can bind zinc and reduce the available ions.

A label tells you the zinc content. It does not tell you how many ions are actually released in your mouth. That is the fundamental limitation of the advice to “take lozenges”.

The capsule: beside the point

A swallowed capsule does not dissolve in the throat. At 15 or 25 mg in a single dose, it falls well short of the total dose in positive trials. The picolinate-versus-citrate debate concerns intestinal absorption, not this use.

The nasal spray: no

A series of 17 cases describes loss of smell after application of zinc gluconate nasal gel, with an immediate burning sensation. Seven of these patients never developed symptoms of infection. A causality analysis involving 25 patients concluded that there was a cause-and-effect relationship.

In June 2009, the FDA warned against several Zicam nasal products, following around 130 reports. Cochrane notes that the intranasal trials did not report anosmia, with uncertain information. That is no reason to try them: the balance between possible benefit and risk is poor for an illness that clears up in one to two weeks.

Dose: the real dilemma

Here is the heart of the problem. EFSA sets the tolerable upper intake level for zinc at 25 mg per day for adults, and lower for children. The MSD Manual uses 40 mg per day.

The doses that produced an effect in the meta-analyses exceed 75 mg per day, more than three times the European limit. That creates a dilemma with no neat solution:

  • At a standard supplement dose, you remain below the threshold at which the positive trials found an effect.
  • At the trial doses, you move outside the range considered safe for routine use.

Hemilä considers serious risk unlikely at 80 to 92 mg per day for one to two weeks, drawing on the use of high doses in Wilson’s disease. This reasoning by analogy deserves consideration, but it does not come from a cold trial. A safety limit is not a cliff edge: it is a threshold beyond which risk is no longer covered by the safety assessment.

The hidden cost of prolonged use

The MSD Manual describes disrupted copper metabolism, reduced blood copper, neutropenia and a weakened immune system at 100 to 150 mg per day over long periods. The product sold to strengthen your defences can therefore weaken them if you keep taking it.

Neurological damage caused by copper deficiency has been documented, notably after prolonged exposure to a zinc-containing denture adhesive. A case report published in 2026 notes that these complications remain rare. They are also avoidable.

Vidal recommends taking zinc at least two hours apart from iron, tetracycline and quinolone antibiotics, osteoporosis treatments and antacids. The guide to supplement interactions covers this further.

What to do at the first sneeze

The basics remain unglamorous and effective: rest, hydration and symptom relief if needed. The NHS explains that antibiotics do not help with a cold because it is caused by a virus. If you are interested in what causes colds, the article on cold temperatures and immunity · FR unpicks what temperature does and does not explain.

If you still want to try a lozenge, doing so only makes sense within a clear framework:

  • Adults only, excluding pregnancy and breastfeeding, with no interacting medication.
  • Start within 24 hours of the first symptoms.
  • A lozenge left to dissolve, preferably with no citric acid or tartaric acid in the formulation.
  • Use the dose stated on the packaging; do not exceed it on your own initiative.
  • Use for a few days, never continuously beyond the duration of the cold.
  • Stop as soon as nausea, stomach upset or bothersome taste disturbances appear.

Aiming for the trial doses, above 75 mg per day, is not a decision to make alone in the supplement aisle. It is a conversation with a pharmacist or doctor who knows your medication and medical history.

When to seek medical advice

The NHS advises seeing a doctor in the following situations:

  • A high temperature lasting more than 3 days.
  • Worsening symptoms.
  • Shortness of breath or chest pain.
  • No improvement after 10 days.
  • A cough lasting more than 3 weeks.
  • A cold in someone with a chronic condition or a weakened immune system.
  • Concern about a child.

These signs warrant medical advice, with or without lozenges. Zinc must never delay that appointment.

The Verdict

Main sources


Frequently Asked Questions (FAQ)

  • Can a zinc capsule shorten a cold?

    The most widely discussed positive findings come from lozenges left to dissolve, at total doses above 75 mg per day. Swallowing a 15 or 25 mg capsule reproduces neither the dose nor the local contact with the throat. There is no basis for assuming the same effect.

  • Can you take zinc all winter to prevent colds?

    The 2024 Cochrane review concludes that zinc produces little or no reduction in the risk of catching a cold. Without a documented deficiency, a winter course therefore has no established benefit, and prolonged high-dose use carries a risk of copper deficiency.

  • Is zinc useful for colds in children?

    The authors who advocate lozenges for adults themselves write that there is no evidence of their effectiveness in children. Safety limits are also lower at that age. Ask a doctor or pharmacist before giving any zinc.

  • Can zinc cause loss of smell?

    The documented risk concerns gels and sprays applied inside the nose, not lozenges. Case series describe loss of smell after nasal application, and the FDA warned against several products in 2009. Do not use any nasal product containing zinc.

Partager cet article

X f in

Keep exploring

View all articles

Supplements

Echinacea for colds: what the trials really say

Read the article

Supplements

Honey for coughs: effectiveness, dose and risks under 1 year

Read the article

Supplements

Elderberry for flu and colds: what the syrups are really worth

Read the article